BOSTON – From the welcoming remarks to the plenary session and workshops, the message to BioPharm America 2012 attendees was loud and clear: Partnering is all about value creation. Read More
Onconova Therapeutics Inc.'s deal with Baxter International Inc. for European rights to rigosertib for myelodysplastic syndromes (MDS) and pancreatic cancer, worth up to $565 million, tops off a string of agreements over the past few years that leaves the company with full U.S. ownership of the late-stage compound. Read More
The latest firm launched by Third Rock Ventures, MyoKardia Inc., started its existence with a $38 million Series A financing, disclosed Thursday morning, to translate discoveries of mutations in the heart muscle into personalized therapeutic approaches for treating genetic cardiomyopathy. Read More
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) found no red flags preventing the use of new tumorigenic cell lines for vaccine production, but had plenty of questions and hypotheticals for the experts gathered at Wednesday's meeting. Read More
Foundation Medicine Inc.'s $42.5 million in a Series B financing will let the company broaden use of its marketed genetic test for mutations key to cancer therapies and, next year, expand marketing from solid tumors to hematological disease. Read More
• Intellect Neurosciences Inc., of New York, and MRC Technology, of London, said they completed humanization of 82E1, a mouse monoclonal antibody to create a high-affinity stabilized IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein. Read More
• Aerpio Therapeutics Inc., of Cincinnati, said it dosed the first patient in a Phase Ib/IIa trial of AKB-9778, a human protein tyrosine phosphate beta inhibitor designed to activate Tie2, for diabetic macular edema. Read More
• Jansen Biotech Inc., of Horsham, Pa., a unit of Johnson & Johnson, said it submitted a biologics license application requesting approval of an intravenous formulation of anti-tumor necrosis factor-alpha drug Simponi (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis. Read More
